Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03221348 | A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma | unknown | Phase 1 | 24 | Cho Pharma Inc.INDUSTRY | 0 | Jan 24, 2018 | clinicaltrials |
| NCT03282825 | Clinical Study of Decitabine and Paclitaxel Combination Therapy | unknown | Phase 1 | 18 | Dong Wha Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03404414 |
| Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT |
| unknown |
| Phase 1 |
| 100 |
| Peking Union Medical College HospitalOTHER |
| 1 |
| Jan 19, 2018 |
| clinicaltrials |
| NCT03175705 | Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC | unknown | Phase 1 | 18 | Beijing YouAn HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03398967 | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02924753 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03383952 | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03383965 | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03040401 | A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) | unknown | Phase 1 / Phase 2 | 15 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03299738 | A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL | unknown | Phase 1 | 10 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03051906 | Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer(DUCRO-HN) | unknown | Phase 1 / Phase 2 | 69 | Azienda Ospedaliero-Universitaria CareggiOTHER | 0 | Nov 22, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03344705 | Safety and Efficacy Evaluation of IM19 Cells | unknown | Phase 1 | 20 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03294486 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients(ONCOVIRAC) | unknown | Phase 1 / Phase 2 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02149459 | Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy(SMC 0712-13) | unknown | Phase 1 | 18 | Sheba Medical CenterOTHER_GOV | 1 | Oct 27, 2017 | clinicaltrials |
| NCT03321448 | TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer | unknown | Phase 1 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT03320772 | TMVP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer | unknown | Phase 1 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT03263208 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 / Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02906800 | Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients(DIGHANC) | unknown | Phase 1 / Phase 2 | 15 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02488382 | Lonquek for Autologous Stem Cell Mobilization | unknown | Phase 1 / Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Oct 17, 2017 | clinicaltrials |
| NCT03311789 | Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT03308682 | 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT03298828 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 | 30 | Third Military Medical UniversityOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02844699 | A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT03235167 | Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy | unknown | Phase 1 | 100 | Dalian UniversityOTHER | 0 | Sep 18, 2017 | clinicaltrials |
| NCT03281551 | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | unknown | Phase 1 | 50 | Pinze Lifetechnology Co. Ltd.INDUSTRY | 1 | Sep 15, 2017 | clinicaltrials |
| NCT03208556 | Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 20 | Peking UniversityOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT03282435 | Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody | unknown | Phase 1 | 30 | Dalian UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03282617 | Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 | 55 | National University Hospital, SingaporeOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT02822326 | Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia | unknown | Phase 1 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT03276156 | Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer | unknown | Phase 1 | 12 | Zhejiang Cancer HospitalOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT02602249 | Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer. | unknown | Phase 1 | 24 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02656147 | Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 | 48 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01793025 | Mismatched Donor Cells to Treat Acute Myeloid Leukemia(ATAC-AML-01) | unknown | Phase 1 | 12 | Maisonneuve-Rosemont HospitalOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02530398 | A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites | unknown | Phase 1 | 48 | Dongfang Hospital Beijing University of Chinese MedicineOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT03260179 | Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 | unknown | Phase 1 | 60 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT03239756 | Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases | unknown | Phase 1 | 40 | Jiangsu T-Mab Biopharma Co.,LtdINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02672995 | Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial | unknown | Phase 1 | 36 | National Taiwan University HospitalOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02429440 | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides(UroRCC) | unknown | Phase 1 / Phase 2 | 40 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT02452307 | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 36 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT01716949 | Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer(HyRec) | unknown | Phase 1 / Phase 2 | 59 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01439750 | Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) | unknown | Phase 1 | 13 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 7, 2017 | clinicaltrials |
| NCT02782351 | Humanized CAR-T Therapy for Treatment of B Cell Malignancy | unknown | Phase 1 / Phase 2 | 50 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Aug 4, 2017 | clinicaltrials |
| NCT03236883 | Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer(HST) | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 2, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jan 24, 2018source: clinicaltrials